-
Mashup Score: 54Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer - 1 month(s) ago
AbstractThe checkpoint immunotherapeutic pembrolizumab induces responses in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (R223) may increase immunogenicity of bone metastases and increase pembrolizumab (P) activity. In a randomized phase II study, we assessed the effect of R223+P compared with R223 on tumor immune infiltration, safety, and clinical outcomes in patients with mCRPC. The primary endpoint was differences in CD4+ and CD8+ T-cell infiltrate in 8-week versus baseline bone metastasis biopsies; secondary endpoints were safety, radiographic progression-free survival (rPFS), and overall survival (OS). Of the 42 treated patients (29 R223+P, 13 R223), 18 R223+P and 8 R223 patients had evaluable paired tumor biopsies. Median fold-change of CD4+ T cells was −0.7 (range: −9.3 to 4.7) with R223+P and 0.1 (−11.1 to 3.7) with R223 (P = 0.66); for CD8+ T cells, median fold-change was −0.6 (−7.4 to 5.3) with R223+P and −1.3 (−3.1 to
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients
Source: ascopubs.orgCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1
Although the benefit of androgen deprivation therapy (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains controversial, clinical evidence is lacking. Recent results indicated that treatment with abiraterone acetate (AA) plus prednisone (P) further suppresses serum testosterone levels over ADT alone, suggesting that continuation of ADT in the treatment of mCRPC…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Hot Seat: Maximizing PARP Inhibitors in CRPC - PER Updates from the Annual Oncology Meeting - 11 month(s) ago
PER Updates from the Annual Oncology Meeting.
Source: event.gotoper.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Post | Feed | LinkedIn - 11 month(s) ago
The World Health Organization (WHO) International Agency for Research on Cancer (IARC) Director Elisabete Weiderpass, MD, MSc, PhD, presented at the monthly Seminars in Genitourinary Oncology (GU) on April 12. The visit was organized by Atish D. Choudhury, MD, PhD, chair of the Gelb Center for Translational Research in GU. Weiderpass shared a vision for reducing the global burden of cancer…
Source: www.linkedin.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Hot Seat: Maximizing PARP Inhibitors in CRPC - PER Updates from the Annual Oncology Meeting - 12 month(s) ago
PER Updates from the Annual Oncology Meeting.
Source: event.gotoper.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Hot Seat: Maximizing PARP Inhibitors in CRPC - PER Updates from the Annual Oncology Meeting - 12 month(s) ago
PER Updates from the Annual Oncology Meeting.
Source: event.gotoper.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Prostatepedia: Metastatic HSPC - 1 year(s) ago
In this issue, we talk about metastatic hormone sensitive prostate cancer.
Source: FlippingBookCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Prostatepedia: Metastatic HSPC - 1 year(s) ago
In this issue, we talk about metastatic hormone sensitive prostate cancer.
Source: FlippingBookCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1In announcing prostate cancer diagnosis, New England Patriots' Josh Kraft urges early detection - 1 year(s) ago
A routine yearly blood test began to show an increasing PSA level, which led to biopsy and then a phone call from his doctor telling him he had cancer.
Source: WCVBCategories: Hem/Oncs, Latest HeadlinesTweet
We are excited to report results of our investigator-initiated randomized Phase 2 trial of radium-223 with or without pembrolizumab in mCRPC initially developed by @LaurenCHarshman and Dr. Lawrence Fong and supported by @Merck and @Bayer. 🧵 https://t.co/5ny535QpGv